Literature DB >> 17043122

Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.

Patrick Schwarz1, Guilhem Janbon, Françoise Dromer, Olivier Lortholary, Eric Dannaoui.   

Abstract

The combination of flucytosine and amphotericin B was tested against 10 flucytosine-resistant isolates of Cryptococcus neoformans by checkerboard, killing curves, and Etest. Although differences were observed depending on the technique used, antagonism was never observed. The synergistic interaction was related to the mechanism of flucytosine resistance of the isolates.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17043122      PMCID： PMC1797681          DOI： 10.1128/AAC.00446-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

1.  In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates.

Authors:  Patrick Schwarz; Françoise Dromer; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

2.  Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial.

Authors:  Annemarie E Brouwer; Adul Rajanuwong; Wirongrong Chierakul; George E Griffin; Robert A Larsen; Nicholas J White; Thomas S Harrison
Journal:  Lancet       Date:  2004-05-29       Impact factor: 79.321

3.  Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.

Authors:  Patrick Schwarz; Françoise Dromer; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

4.  Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species.

Authors:  R E Lewis; D J Diekema; S A Messer; M A Pfaller; M E Klepser
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

5.  Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.

Authors:  E Dannaoui; M Abdul; M Arpin; A Michel-Nguyen; M A Piens; A Favel; O Lortholary; F Dromer
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

6.  Development of positive selectable markers for the fungal pathogen Cryptococcus neoformans.

Authors:  J Hua; J D Meyer; J K Lodge
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

7.  Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms.

Authors:  G Medoff; M Comfort; G S Kobayashi
Journal:  Proc Soc Exp Biol Med       Date:  1971-11

8.  Flucytosine primary resistance in Candida species and Cryptococcus neoformans.

Authors:  M Cuenca-Estrella; T M Díaz-Guerra; E Mellado; J L Rodríguez-Tudela
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2001-04       Impact factor: 3.267

9.  Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.

Authors:  M E Brandt; M A Pfaller; R A Hajjeh; R J Hamill; P G Pappas; A L Reingold; D Rimland; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

10.  In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach.

Authors:  D T A Te Dorsthorst; P E Verweij; J Meletiadis; M Bergervoet; N C Punt; J F G M Meis; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191
View more
  17 in total

1.  Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine.

Authors:  A Espinel-Ingroff; A Chowdhary; M Cuenca-Estrella; A Fothergill; J Fuller; F Hagen; N Govender; J Guarro; E Johnson; C Lass-Flörl; S R Lockhart; M A Martins; J F Meis; M S C Melhem; L Ostrosky-Zeichner; T Pelaez; M A Pfaller; W A Schell; L Trilles; S Kidd; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

2.  Cryptococcal osteomyelitis in an adolescent survivor of T-cell acute lymphoblastic leukemia.

Authors:  Djin-Ye Oh; P Pallavi Madhusoodhan; Deborah J Springer; Kenneth Inglima; Ali A Chaudhri; Joseph Heitman; Elizabeth A Raetz; Alka Khaitan; Mona Rigaud
Journal:  Pediatr Infect Dis J       Date:  2015-06       Impact factor: 2.129

3.  Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.

Authors:  George R Thompson; Nathan P Wiederhold; Annette W Fothergill; Ana C Vallor; Brian L Wickes; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

4.  In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.

Authors:  Maria-Teresa Illnait-Zaragozi; Gerardo F Martínez; Ilse Curfs-Breuker; Carlos M Fernández; Teun Boekhout; Jacques F Meis
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

5.  Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

Authors:  John R Perfect; William E Dismukes; Francoise Dromer; David L Goldman; John R Graybill; Richard J Hamill; Thomas S Harrison; Robert A Larsen; Olivier Lortholary; Minh-Hong Nguyen; Peter G Pappas; William G Powderly; Nina Singh; Jack D Sobel; Tania C Sorrell
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

Review 6.  Virulence-Associated Enzymes of Cryptococcus neoformans.

Authors:  Fausto Almeida; Julie M Wolf; Arturo Casadevall
Journal:  Eukaryot Cell       Date:  2015-10-09

7.  Comparative effectiveness of induction therapy for human immunodeficiency virus-associated cryptococcal meningitis: a network meta-analysis.

Authors:  Jeffrey I Campbell; Steve Kanters; John E Bennett; Kristian Thorlund; Alexander C Tsai; Edward J Mills; Mark J Siedner
Journal:  Open Forum Infect Dis       Date:  2015-02-26       Impact factor: 3.835

8.  Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study.

Authors:  Françoise Dromer; Simone Mathoulin-Pélissier; Odile Launay; Olivier Lortholary
Journal:  PLoS Med       Date:  2007-02       Impact factor: 11.069

9.  Major role for amphotericin B-flucytosine combination in severe cryptococcosis.

Authors:  Françoise Dromer; Claire Bernede-Bauduin; Didier Guillemot; Olivier Lortholary
Journal:  PLoS One       Date:  2008-08-06       Impact factor: 3.240

Review 10.  Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal.

Authors:  Angela Loyse; Françoise Dromer; Jeremy Day; Olivier Lortholary; Thomas S Harrison
Journal:  J Antimicrob Chemother       Date:  2013-06-20       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.